CN103998056B - 用于接种抗金黄色葡萄球菌疫苗的方法和组合物 - Google Patents

用于接种抗金黄色葡萄球菌疫苗的方法和组合物 Download PDF

Info

Publication number
CN103998056B
CN103998056B CN201280046321.4A CN201280046321A CN103998056B CN 103998056 B CN103998056 B CN 103998056B CN 201280046321 A CN201280046321 A CN 201280046321A CN 103998056 B CN103998056 B CN 103998056B
Authority
CN
China
Prior art keywords
application according
staphylococcus aureus
vaccine
als3p
ndv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280046321.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN103998056A (zh
Inventor
迈克尔·R·伊曼
小约翰·E·爱德华兹
斯科特·G·菲勒
阿什拉夫·S·易卜拉欣
傅悦
小约翰·P·亨尼西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOS ANGELES BIOMEDICAL RES INS
Nova Di Gemu Therapy Co Ltd
Original Assignee
LOS ANGELES BIOMEDICAL RES INS
Nova Di Gemu Therapy Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOS ANGELES BIOMEDICAL RES INS, Nova Di Gemu Therapy Co Ltd filed Critical LOS ANGELES BIOMEDICAL RES INS
Publication of CN103998056A publication Critical patent/CN103998056A/zh
Application granted granted Critical
Publication of CN103998056B publication Critical patent/CN103998056B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201280046321.4A 2011-07-22 2012-07-20 用于接种抗金黄色葡萄球菌疫苗的方法和组合物 Expired - Fee Related CN103998056B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161510896P 2011-07-22 2011-07-22
US61/510,896 2011-07-22
PCT/US2012/000328 WO2013015831A1 (en) 2011-07-22 2012-07-20 Methods and compositions for vaccinating against staphylococcus aureus

Publications (2)

Publication Number Publication Date
CN103998056A CN103998056A (zh) 2014-08-20
CN103998056B true CN103998056B (zh) 2017-09-12

Family

ID=47601425

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280046321.4A Expired - Fee Related CN103998056B (zh) 2011-07-22 2012-07-20 用于接种抗金黄色葡萄球菌疫苗的方法和组合物

Country Status (12)

Country Link
US (1) US10653757B2 (https=)
EP (1) EP2734229B1 (https=)
JP (1) JP2014521605A (https=)
CN (1) CN103998056B (https=)
AU (1) AU2012287513A1 (https=)
BR (1) BR112014001409A2 (https=)
CA (1) CA2842626A1 (https=)
EA (1) EA035513B1 (https=)
ES (1) ES2716800T3 (https=)
GE (1) GEP201706766B (https=)
UA (1) UA114286C2 (https=)
WO (1) WO2013015831A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077256A1 (en) * 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
GEP201706766B (en) 2011-07-22 2017-10-25 Los Angeles Biomedical Res Center Methods and compositions for vaccinating against staphylococcus aureus
US11198724B2 (en) 2013-03-14 2021-12-14 The Regents Of The University Of Michigan Treatment of staphylococcal disorders
JP6348967B2 (ja) * 2013-03-14 2018-06-27 ワン、ロンフ 制御性ｔ細胞機能を調節する方法および組成物
US10130691B2 (en) * 2013-03-15 2018-11-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods for treating fungal and bacterial pathogens
EP3426287A4 (en) * 2016-03-09 2020-03-11 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Methods and kits for use in preventing and treating vulvovaginal candidiasis
CN105713096B (zh) * 2016-03-29 2019-01-01 黑龙江八一农垦大学 一种预防金黄色葡萄球菌感染的att融合蛋白的制备及应用
AU2018379996A1 (en) 2017-12-05 2020-06-25 BioPlx, Inc. Methods and compositions to prevent microbial infection
JP7439371B2 (ja) 2018-04-10 2024-02-28 ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー－ ユーシーエルエー メディカル センター Ｃａｎｄｉｄａ ａｕｒｉｓ感染症の治療方法
CN112940987B (zh) * 2021-04-10 2022-10-14 福建省农业科学院畜牧兽医研究所 一株兔金黄色葡萄球菌及其在制备灭活疫苗中的应用
US20220354935A1 (en) * 2021-04-21 2022-11-10 Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center Vaccination against fungal epitopes to prevent inflammatory bowel diseases
WO2025032534A2 (en) * 2023-08-09 2025-02-13 Glaxosmithkline Biologicals Sa Modified proteins
WO2025240443A1 (en) * 2024-05-14 2025-11-20 University Of Rochester Candida for use in prevention or mitigation of cutaneous viral infections

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241613B1 (en) * 2002-06-05 2007-07-10 Oscient Pharmaceuticals Corporation Identification of Candida cell surface proteins and their uses

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346074A (en) 1978-08-24 1982-08-24 National Research Development Corp. Pasteurellosis vaccines
US5622939A (en) 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
EP1624068A1 (en) 1993-06-01 2006-02-08 Life Technologies Inc. Genetic immunization with cationic lipids
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
WO1995031998A1 (en) 1994-05-23 1995-11-30 The Research & Development Institute, Inc. Candida albicans adhesin as a vaccine
US5668263A (en) 1994-12-16 1997-09-16 Smithkline Beecham Corporation Conserved yeast nucleic acid sequences
US6500438B2 (en) 1995-06-07 2002-12-31 Pfizer Incorporated In ovo vaccination against coccidiosis
DE69734601T2 (de) 1996-05-16 2006-08-03 The Texas A & M University System, College Station Zusammensetzung von kollagenbindungsprotein und verfahren zu deren verwendungen
US6747137B1 (en) 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
US6248329B1 (en) 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
US6703025B1 (en) 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
US20060083750A1 (en) 1999-11-19 2006-04-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
US7067138B1 (en) 1999-11-19 2006-06-27 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
US8541008B2 (en) * 1999-11-19 2013-09-24 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against candidiasis
US20070077256A1 (en) * 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
EP2319301B1 (en) 2001-11-30 2017-09-06 Amgen Fremont Inc. Transgenic animals bearing human Ig lambda light chain genes
AU2003231818B2 (en) 2002-05-21 2007-04-19 Intervet International B.V. Methods for the in vitro culture of Sporozoea sp. and user thereof
AU2003290867A1 (en) 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
MXPA06005639A (es) * 2003-11-21 2006-08-17 Pfizer Prod Inc Adyuvante antimicrobiano.
US20050287146A1 (en) 2003-12-19 2005-12-29 Joseph Patti Method of inhibiting Candida-related infections using donor selected or donor stimulated immunoglobulin compositions
GB0420466D0 (en) 2004-09-14 2004-10-20 Cassone Antonio Anti-glucan antibodies
WO2006036817A2 (en) 2004-09-24 2006-04-06 Microbia, Inc. Fungal variants and uses thereof
CA2489194A1 (en) 2004-12-03 2006-06-03 Guilhem Janbon Polypeptides involved in candida biofilm formation and uses thereof
WO2007126813A2 (en) 2006-03-29 2007-11-08 Inhibitex, Inc. Cross-reactive monoclonal antibodies recognizing als family proteins
BRPI0711572A2 (pt) 2006-04-17 2011-11-16 Schering Plough Ltd organismos recombinantes atenuados de clostridium e vacinas
EP2164511A1 (en) 2007-05-22 2010-03-24 Baylor College Of Medicine Immune complex vaccination as a strategy to enhance immunity in the elderly and other immune compromised populations
EP2039764A1 (en) * 2007-09-19 2009-03-25 Pevion Biotech AG Truncated secretory aspartyl proteinase 2
US9050281B2 (en) 2008-05-29 2015-06-09 Intervet Inc. Coccidiosis vaccines
US20100150942A1 (en) 2008-12-03 2010-06-17 Cantor Thomas L Affinity purified human polyclonal antibodies and methods of making and using them
SA110310528B1 (ar) * 2009-06-22 2014-07-02 Wyeth Llc التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس
WO2011003085A1 (en) 2009-07-03 2011-01-06 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Hyr1 as a target for active and passive immunization against candida
WO2012163533A1 (en) 2011-06-01 2012-12-06 Eth Zurich T cell epitope of candida albicans
GEP201706766B (en) 2011-07-22 2017-10-25 Los Angeles Biomedical Res Center Methods and compositions for vaccinating against staphylococcus aureus
GB201503812D0 (en) 2015-03-06 2015-04-22 Univ Aberdeen Antibody molecules and uses thereof
EP3426287A4 (en) 2016-03-09 2020-03-11 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Methods and kits for use in preventing and treating vulvovaginal candidiasis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241613B1 (en) * 2002-06-05 2007-07-10 Oscient Pharmaceuticals Corporation Identification of Candida cell surface proteins and their uses

Also Published As

Publication number Publication date
US10653757B2 (en) 2020-05-19
EP2734229B1 (en) 2019-01-02
BR112014001409A2 (pt) 2017-07-11
GEP201706766B (en) 2017-10-25
WO2013015831A1 (en) 2013-01-31
US20150273031A1 (en) 2015-10-01
AU2012287513A8 (en) 2014-06-19
CA2842626A1 (en) 2013-01-31
UA114286C2 (uk) 2017-05-25
EP2734229A4 (en) 2015-01-21
ES2716800T3 (es) 2019-06-17
JP2014521605A (ja) 2014-08-28
EA035513B1 (ru) 2020-06-29
EA201391200A1 (ru) 2014-05-30
AU2012287513A1 (en) 2014-03-13
CN103998056A (zh) 2014-08-20
EP2734229A1 (en) 2014-05-28

Similar Documents

Publication Publication Date Title
CN103998056B (zh) 用于接种抗金黄色葡萄球菌疫苗的方法和组合物
JP7072921B2 (ja) Ａ群レンサ球菌ワクチン
CN101107009B (zh) 包含纤连蛋白结合蛋白或纤连蛋白结合肽的疫苗组合物
EP2968497B1 (en) Compositions and methods for treating fungal and bacterial pathogens
EA025831B1 (ru) Композиции из hyr1-производных и способы лечения ими
JP2019507759A (ja) 外陰部膣カンジダ症の予防及び治療で使用するための方法及びキット
JP2021514387A (ja) ブドウ球菌抗原を含む免疫原性組成物
JP5661744B2 (ja) 腸球菌由来のポリペプチド、及びワクチン接種のためのその使用
US9926342B2 (en) Recombinant VapA and VapC peptides and uses thereof
Ma et al. Immunogenicity of multi-epitope vaccines composed of epitopes from Streptococcus dysgalactiae GapC
CN110996994A (zh) 加强免疫应答的方法
JP2020536968A (ja) 共生疾患進行に対する包括的ワクチン設計
WO2022155403A1 (en) Recombinant polypeptides, conjugates comprising the same, and uses thereof
KR20190039022A (ko) 샤가스 항원 및 항체, 및 이들의 조성물, 방법 및 용도
Khosravani pour et al. Enhanced immunogenicity of Staphylococcus aureus IsdE vaccine with SeNPs and BCG adjuvants in mice
Haghighat et al. Enhanced immunogenicity of Staphylococcus aureus IsdE vaccine with SeNPs and BCG adjuvants in mice
CN114073762B (zh) 一种含有Omp19和VirB8蛋白的布鲁氏菌病双组分疫苗
Zhang Research progress on the role of immune cells in Brucella infection
CN111088269B (zh) OprJ-N-M融合基因及其融合蛋白、融合蛋白制备方法以及用途
Hassanzadeh Enhanced immunogenicity of Staphylococcus aureusIsdE vaccine with SeNPs and BCG adjuvants in mice
Smith et al. Group B meningococcal outer membrane protein vaccine promote potent anti-viral effect
US20110171224A1 (en) PsrP IS A PROTECTIVE ANTIGEN AGAINST PNEUMOCOCCAL INFECTION
US20230045642A1 (en) S. aureus antigens and compositions thereof
WO2025219610A1 (en) A vaccine for the treatment or prevention of pseudomonas aeruginosa infection in a subject.
CN117603319A (zh) 鲍曼不动杆菌多抗原表位多肽rOmpW及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170912

Termination date: 20210720

CF01 Termination of patent right due to non-payment of annual fee